Carson Advisory Inc. Has $1.60 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Carson Advisory Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 1.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,142 shares of the company’s stock after buying an additional 167 shares during the period. Johnson & Johnson accounts for approximately 1.1% of Carson Advisory Inc.’s investment portfolio, making the stock its 21st biggest holding. Carson Advisory Inc.’s holdings in Johnson & Johnson were worth $1,604,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson in the 1st quarter valued at about $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $40,000. WFA Asset Management Corp lifted its position in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at about $45,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on JNJ shares. Bank of America dropped their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $149.69 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $360.26 billion, a PE ratio of 9.33, a price-to-earnings-growth ratio of 2.49 and a beta of 0.52. The firm’s 50 day moving average is $147.92 and its 200 day moving average is $153.54. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the business earned $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.31%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.